By 2050, there will be 25.2 million people living with Parkinson's disease worldwide (a 112% increase from 2021), largely due to population ageing, suggests a modelling study published by The BMJ ...

Vanegas, a transfer student who is set to graduate from the Rutgers School of Social Work in May. “I’ve just always liked to ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...